Hexagon Bio

Hexagon Bio develops targeted small molecule therapeutics using a proprietary platform that combines data science, genomics, synthetic biology, chemistry, and automation. The company mines fungal genomes to discover potent small molecules and their targets for the next generation of targeted therapies, including next-generation antibody drug conjugate (ADC) payloads for cancer.